253 467

Cited 74 times in

Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes

DC Field Value Language
dc.contributor.author강신욱-
dc.date.accessioned2015-06-10T12:21:05Z-
dc.date.available2015-06-10T12:21:05Z-
dc.date.issued2006-
dc.identifier.issn0952-5041-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/109642-
dc.description.abstractAngiotensin II (Ang-II) and vascular endothelial growth factor (VEGF) have an important role in the pathogenesis of diabetic nephropathy, but the signaling cascade of VEGF regulation in response to Ang-II in podocytes is largely unknown. In these experiments, we looked at the effect of Ang-II on the production of VEGF, and investigated whether VEGF production depends on the p38 mitogen activated protein kinase (MAPK) pathway in cultured mouse podocytes. Incubation of podocytes with Ang-II induced a rapid increase in VEGF mRNA expression and protein synthesis as well as its transcriptional activity in an Ang-II dose-dependent manner. To further define the role of angiotensin type 1 (AT1) and type 2 (AT2) receptors involved in Ang-II-mediated VEGF synthesis, the effects of selective AT1 and AT2 receptor antagonists were evaluated. Prior treatment with losartan significantly inhibited VEGF mRNA and protein synthesis induced by Ang-II, which suggests that the AT1 receptor is involved in Ang-II-mediated VEGF synthesis. Furthermore, stimulation of the cells with Ang-II increased both phosphorylation of p38 MAPK and MAP kinase kinase 3/6 (MKK3/6). Additionally, Ang-II enhanced the DNA binding activity to cAMP response element binding protein (CREB) and phosphorylation of CREB. In addition, to investigate the role of p38 MAPK in Ang-II-induced VEGF synthesis, podocytes were pretreated with or without the p38 MAPK inhibitor, SB203580 for 24 h to observe whether Ang-II-mediated VEGF synthesis was inhibited by blocking p38 MAPK. The addition of SB203580 led to a marked inhibition of the increased VEGF mRNA and protein production induced by Ang-II in a dose-dependent manner. Taken together, these results suggest that Ang-II stimulates the synthesis of VEGF in podocytes and the production of VEGF induced by Ang-II is mediated, in part, through the activation of the p38 MAPK pathway.-
dc.description.statementOfResponsibilityopen-
dc.format.extent377~388-
dc.relation.isPartOfJOURNAL OF MOLECULAR ENDOCRINOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAngiotensin II/pharmacology*-
dc.subject.MESHAnimals-
dc.subject.MESHCells, Cultured-
dc.subject.MESHCyclic AMP Response Element-Binding Protein/metabolism-
dc.subject.MESHElectrophoretic Mobility Shift Assay-
dc.subject.MESHEnzyme Activation/drug effects-
dc.subject.MESHImidazoles/pharmacology-
dc.subject.MESHMAP Kinase Kinase 3/metabolism-
dc.subject.MESHMAP Kinase Kinase 6/metabolism-
dc.subject.MESHMAP Kinase Signaling System*/drug effects-
dc.subject.MESHMice-
dc.subject.MESHPodocytes/drug effects*-
dc.subject.MESHPodocytes/metabolism*-
dc.subject.MESHProtein Kinase Inhibitors/pharmacology-
dc.subject.MESHPyridines/pharmacology-
dc.subject.MESHRNA, Messenger/genetics-
dc.subject.MESHResponse Elements-
dc.subject.MESHTranscriptional Activation/drug effects-
dc.subject.MESHUp-Regulation/drug effects-
dc.subject.MESHVascular Endothelial Growth Factor A/biosynthesis*-
dc.subject.MESHVascular Endothelial Growth Factor A/genetics-
dc.subject.MESHp38 Mitogen-Activated Protein Kinases/antagonists & inhibitors-
dc.subject.MESHp38 Mitogen-Activated Protein Kinases/metabolism*-
dc.titleAngiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorYoung Sun Kang-
dc.contributor.googleauthorYun Gyu Park-
dc.contributor.googleauthorBo Kyung Kim-
dc.contributor.googleauthorSang Youb Han-
dc.contributor.googleauthorYi Hwa Jee-
dc.contributor.googleauthorKum Hyun Han-
dc.contributor.googleauthorMi Hwa Lee-
dc.contributor.googleauthorHye Kyoung Song-
dc.contributor.googleauthorDae Ryong Cha-
dc.contributor.googleauthorShin Wook Kang-
dc.contributor.googleauthorDae Suk Han-
dc.identifier.doi10.1677/jme.1.02033-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00053-
dc.relation.journalcodeJ01606-
dc.identifier.eissn1479-6813-
dc.identifier.pmid16595708-
dc.contributor.alternativeNameKang, Shin Wook-
dc.contributor.affiliatedAuthorKang, Shin Wook-
dc.rights.accessRightsfree-
dc.citation.volume36-
dc.citation.number2-
dc.citation.startPage377-
dc.citation.endPage388-
dc.identifier.bibliographicCitationJOURNAL OF MOLECULAR ENDOCRINOLOGY, Vol.36(2) : 377-388, 2006-
dc.identifier.rimsid38889-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.